Showing 4711-4720 of 5623 results for "".
- Oxford Says AstraZeneca Trial Illnesses May Not Be Linked to COVID-19 Vaccinehttps://modernod.com/news/oxford-says-astrazeneca-trial-illnesses-may-not-be-linked-to-covid-19-vaccine/2478290/Neurological symptoms developed by some volunteers in a trial testing AstraZeneca’s COVID-19 vaccine candidate AZD1222 either probably did not come about as a result of the vaccine, or there is not enough evidence to say one way or the other, according to the University of Oxford. The discl
- Santen Acquires Eyevance Pharmaceuticalhttps://modernod.com/news/santen-acquires-eyevance-pharmaceutical/2478289/In a move to enter the US pharmaceuticals market and expand its global presence, Santen announced it has acquired Eyevance Pharmaceutical for $225 million in cash. In the deal, Santen Holdings U.S. Inc., a wholly-owned subsidiary of Santen, will acquire all of the outstanding shares of Ey
- Facebook and EssilorLuxottica Announce Collaboration for Smart Glasseshttps://modernod.com/news/facebook-and-essilorluxottica-announce-collaboration-for-smart-glasses/2478288/Facebook and EssilorLuxottica announced a multiyear collaboration to develop the next generation of smart glasses. The announcement was made by Mark Zuckerberg during Facebook Connect, an annual conference held virtually from California. Terms of the deal were not disclosed. The par
- Recordati Rare Diseases Announces Availability of Cystadrops in the UShttps://modernod.com/news/recordati-rare-diseases-announces-availability-of-cystadrops-in-the-us/2478283/Recordati Rare Diseases announced that Cystadrops (cysteamine ophthalmic solution) 0.37% is now available for prescription and distribution across the United States. Cystadrops is a new, viscous eye drop solution that depletes cystine crystal deposits in the corne
- Researchers Are Able to Visualize the Retina’s Function at the Cellular Levelhttps://modernod.com/news/researchers-are-able-to-visualize-the-retinas-function-at-the-cellular-level/2478271/While there is no cure for blindness and macular degeneration, scientists have accelerated the process to find a cure by visualizing the inner workings of th
- HelpMeSee Names Saro Jahani As President and CEOhttps://modernod.com/news/helpmesee-names-saro-jahani-as-president-and-ceo/2478266/Nonprofit HelpMeSee announced the appointment of Saro Jahani as President and CEO. He will also join the Board of Directors. Mr. Jahani succeeds Jacob Mohan Thazahathu, who retired after 10 years of service. Mr. Jahani
- Study to Investigate If Those With Diabetic Eye Disease Are At Greater Risk of COVID-19 Complicationshttps://modernod.com/news/study-to-investigate-if-those-with-diabetic-eye-disease-are-at-greater-risk-of-covid-19-complications/2478267/Fight for Sight is partnering with Diabetes UK to investigate if people with diabetic retinopathy are at greater risk of developing complications from COVID-19, in a study that hopes to save lives. This research, which will be carried out at the University of Edinburgh, will investigate wh
- The Vision Council Launches New Brand Identity and Member-Focused Websitehttps://modernod.com/news/the-vision-council-launches-new-brand-identity-and-member-focused-website/2478260/The Vision Council announced the launch of a new brand identity, including a reimagined logo and a new website designed to better serve and accommodate the needs of members and the vision care community at large. The rebrand and website launch represent the initial phase of the plan The Vision Co
- Regenxbio Announces Dosing of First Patient in Phase 2 AAVIATE Trial of RGX-314 for the Treatment of Wet AMDhttps://modernod.com/news/regenxbio-announces-dosing-of-first-patient-in-phase-2-aaviate-trial-of-rgx-314-for-the-treatment-of-wet-amd/2478257/Regenxbio announced that the first patient has been dosed in the AAVIATE trial, a phase 2 trial to evaluate the suprachoroidal delivery of RGX-314 using the SCS Microinjector for the treatment of wet age-related macular degeneration (AMD). The company expects to report interim data from the first
- AMA Issues CPT Category III Codes for Artificial Iris Implantationhttps://modernod.com/news/ama-issues-cpt-category-iii-codes-for-artificial-iris-implantation/2478255/VEO Ophthalmics announced that the American Medical Association (AMA) has issued three CPT codes for the “Insertion of Iris Prosthesis.” The CPT Category III codes are: 0616T, 0617T, and 0618T and are effective July 1, 2020. Earlier this year, the